Thousands of pancreatic cancer patients tracked in new drug study
NCT ID NCT06375473
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 3,000 pancreatic cancer patients in China who are receiving irinotecan liposome II as part of their treatment. Researchers will collect data on side effects, survival, and how well the drug controls the cancer. The goal is to understand how this treatment works in real-world settings, outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
irinotecan liposome II
What this could lead to
If successful, this study could provide clearer evidence on how well irinotecan liposome II works for pancreatic cancer in everyday medical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient differences. It does not test a new treatment but gathers data on existing use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Cancer Hospital
RECRUITINGHefei, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Provincial People's Hospital
RECRUITINGHenan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ningbo Medical Center Lihuili Hospital
RECRUITINGNingbo, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Unicersity First Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Renji，Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, Guangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wuhan Union Hospital of China
RECRUITINGWuhan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••